We describe a prostate cancer patient whose initial symptom was intermittent double vision. Intracranial magnetic resonance imaging demonstrated a pituitary mass extending to the cavernous sinus, which caused the double vision. After hormonal therapy for prostate cancer, the pituitary mass disappeared, and double vision was completely resolved without local therapy for the brain. In the 19 months of follow-up after hormone treatment, the prostate cancer remained stable, and the patient remained neurologically intact.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.urology.2004.04.073 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intravenous Tranexamic Acid Does Not Improve Visual Field Clarity During Hip Arthroscopy: A Double-Blind, Randomized, Placebo-Controlled Trial.
Arthroscopy
January 2025
Department of Orthopaedic Surgery, Hospital for Special Surgery, New York, NY, USA.
Purpose: To determine the effectiveness of administering intravenous (IV) tranexamic acid (TXA) on altering visual field clarity (VFC) during arthroscopic hip preservation surgery for patients with femoroacetabular impingement syndrome (FAIS).
Methods: This randomized, double-blind, parallel-design trial was conducted over a seven-month period between October 2023 and May 2024 at a single tertiary musculoskeletal hospital. Inclusion criteria included consecutive patients that were diagnosed with FAIS through clinical history, physical exam and advanced imaging and indicated for hip arthroscopy after having failed conservative management.
Purpose: Carotid-cavernous fistulas (CCFs) are abnormal connections between the carotid artery and cavernous sinus, often causing ocular symptoms like chemosis, proptosis, and diplopia. Endovascular embolization is the preferred treatment, typically performed via the transfemoral transvenous route through the inferior petrosal sinus (IPS). However, we present a case and a systematic review of indirect CCF treated through deep orbital puncture of the superior ophthalmic vein (SOV) for embolization.
View Article and Find Full Text PDFLorlatinib Induced Blindness: A Rare Entity.
Pract Radiat Oncol
January 2025
Department of Radiation Oncology, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey. Electronic address:
Lorlatinib is a central nervous system (CNS) penetrant third generation tyrosine kinase inhibitor (TKI) approved for the first line management of metastatic non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) rearrangement [1] which accounts for 3-5% of NSCLC cases [2]. The most commonly reported side effects include hyperlipidemia, edema, peripheral neuropathy and CNS effects [2]. While ocular side effects such as photopsia, blurred vision, vitreous floaters and diplopia have been documented with another ALK TKI, crizotinib, there are few reports of such effects with lorlatinib [3].
View Article and Find Full Text PDFSupporting vision-language model few-shot inference with confounder-pruned knowledge prompt.
Neural Netw
January 2025
National Key Laboratory of Space Integrated Information System, Institute of Software Chinese Academy of Sciences, Beijing, China; University of Chinese Academy of Sciences, Beijing, China.
Vision-language models are pre-trained by aligning image-text pairs in a common space to deal with open-set visual concepts. Recent works adopt fixed or learnable prompts, i.e.
View Article and Find Full Text PDFDynamic Accommodation Responses in Subjects Wearing Myopia Control Spectacles Modifying Peripheral Refraction.
Invest Ophthalmol Vis Sci
January 2025
Laboratorio de Óptica, Universidad de Murcia, Campus de Espinardo, Murcia, Spain.
Purpose: Peripheral optics have been suggested to play a role in myopia progression, with accommodation responses also considered a potential contributor. This study aimed to investigate whether modifications in peripheral optics through different spectacle lenses affect accommodation responses.
Methods: Dynamic accommodation responses were assessed using a double-pass instrument while switching the target from distance (3 m for 3 seconds) to near (0.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!